Your browser doesn't support javascript.
loading
Best practices for evaluation of bone marrow in nonclinical toxicity studies.
Reagan, William J; Irizarry-Rovira, Armando; Poitout-Belissent, Florence; Bolliger, Anne Provencher; Ramaiah, Shashi K; Travlos, Greg; Walker, Dana; Bounous, Denise; Walter, Gail.
  • Reagan WJ; Pfizer Global Research and Development, Drug Safety Research and Development, 8274/1203 Eastern Point Rd., Groton, CT 06340, USA. william.j.reagan@pfizer.com
Vet Clin Pathol ; 40(2): 119-34, 2011 Jun.
Article en En | MEDLINE | ID: mdl-21631562
ABSTRACT
This manuscript is intended to provide a best practice approach to accurately and consistently assess toxicant-induced bone marrow effects of test articles. In nonclinical toxicity studies, complete blood count data in conjunction with the histological examination of the bone marrow are recommended as the foundation for assessing the effect of test articles on the hematopoietic system. This approach alone can be used successfully in many studies. However, in some situations it may be necessary to further characterize effects on the different hematopoietic lineages, either by cytological or flow cytometric evaluation of the bone marrow. Both modalities can be used successfully, and which one is selected will depend on the expertise, preference of the facility, and the nature of the change in the bone marrow. Other specialized techniques such as clonogenic assays or electron microscopy are used rarely to further characterize hematotoxicity. The indications and techniques to successfully employ histological, cytological, or flow cytometric evaluation as well as clonogenic assays and electron microscopy are reviewed.

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Año: 2011 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Año: 2011 Tipo del documento: Article